Previous studies have shown that targeting Rap1A and inhibiting T cells infiltration alleviate diabetic peripheral neuropathic pain in mice [36], and Rap1B may prevent excessive vascular leakage in patients with early diabetes through suppressing VEGF signaling [37]. This evidence concerns the gene RAP1A and diabetes mellitus.